Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nanobiotix
  6. News
  7. Summary
    NANO   FR0011341205

NANOBIOTIX

(NANO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nanobiotix Enrolls First Patient In Late-Stage Trial For Head, Neck Cancer Treatment

01/05/2022 | 11:09pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about NANOBIOTIX
05/18CORRECTING AND REPLACING : NANOBIOTIX Provides First Quarter Operational and Financial Upd..
BU
05/18NANOBIOTIX Provides First Quarter Operational and Financial Update
BU
05/18NANOBIOTIX : 1st quarter results
CO
05/17NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
BU
05/11NANOBIOTIX to Participate in Two Upcoming Investor Conferences
BU
05/04NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
BU
05/02New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022..
BU
04/30NANOBIOTIX : Monthly statement on outstanding equity shares and voting rights
CO
04/11Nanobiotix's Radiotherapy-activated Combination Therapy Shows Improved Anti-tumor Immun..
MT
04/11NANOBOTIX : New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation v..
PU
More news
Analyst Recommendations on NANOBIOTIX
More recommendations
Financials
Sales 2022 1,25 M 1,32 M 1,32 M
Net income 2022 -52,1 M -55,0 M -55,0 M
Net Debt 2022 24,4 M 25,8 M 25,8 M
P/E ratio 2022 -3,43x
Yield 2022 -
Capitalization 179 M 189 M 189 M
EV / Sales 2022 163x
EV / Sales 2023 134x
Nbr of Employees 100
Free-Float 94,5%
Chart NANOBIOTIX
Duration : Period :
Nanobiotix Technical Analysis Chart | NANO | FR0011341205 | MarketScreener
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 5,14 €
Average target price 22,90 €
Spread / Average Target 346%
EPS Revisions
Managers and Directors
Laurent Lévy Chairman-Executive Board & Chief Executive Officer
Bart van Rhijn Chief Financial Officer
Gary M. Phillips Chairman-Supervisory Board
Margaret Galluzzi Vice President-Global & Head-Clinical Operations
Alain Dostie Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
NANOBIOTIX-29.69%189
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567